Please login to the form below

Not currently logged in
Email:
Password:

Lonquex

This page shows the latest Lonquex news and features for those working in and with pharma, biotech and healthcare.

Cuts help Teva raise profits, despite flat sales

Cuts help Teva raise profits, despite flat sales

Teva's specialty medicines business also benefitted from the introduction of biosimilar filgrastim (G-CSF) products Lonquex and Granix, which have captured market share of around 10% in the markets they

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Neulasta rival from Teva cleared in EU. Lonquex offers competition to Amgen drug in neutropaenia. ... Lonquex is the first biologic medicine from Teva's branded medicines division to be approved for marketing.

  • EMA backs Pomalidomide Celgene in multiple myeloma EMA backs Pomalidomide Celgene in multiple myeloma

    Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics